Senior Manager Biostatistic
Showing salary data for 266 Senior Manager Biostatistic positions
In-depth H-1B visa salary data for Senior Manager Biostatistic positions across the United States. Explore compensation trends, top employers, and geographic distribution for this specialty occupation. Compare wages across different companies and cities.
Job Title Stats
Total Positions
266
Average Salary
$126,476.11
About Senior Manager Biostatistic
The role of a Senior Manager, Biostatistics is pivotal in the pharmaceutical and biotechnology industries, focusing on the design and analysis of clinical trials. Professionals in this position are responsible for leading statistical teams, developing statistical methodologies, and ensuring compliance with regulatory standards. Key skills include proficiency in statistical software, strong analytical abilities, and excellent communication skills. With an average salary of approximately $102K and 13 H-1B positions available in 2024, this role presents significant opportunities for international professionals seeking visa sponsorship. The demand for biostatisticians is growing, driven by advancements in personalized medicine and data analytics, making this an attractive career path with promising growth potential.
Monthly H-1B Job Count & Salaries
Top Locations for Senior Manager Biostatistic
* Dominance shows what proportion of all H-1B jobs in each city are for the Senior Manager Biostatistic role.
💰 Salary Trends & Insights
The salary trends for Senior Manager, Biostatistics positions from January 2020 to June 2025 show fluctuations, with an overall average salary of $126,476. Notably, 2023 experienced a peak average salary of $136,498, despite a decline in 2024 to $103,456. The highest recent average salary was $137,218 in June 2025, indicating a recovery. Job postings peaked in 2022 with 106 listings, while 2023 and 2020 also saw significant activity. This role's compensation has evolved, reflecting market demand and economic conditions, with notable increases in 2023 and 2025.